Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.36
(
-1.29%
)
Bitcoin
74,535.16
(
0.80%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ariadndndough post# 116934

Thursday, 01/12/2012 10:51:08 PM

Thursday, January 12, 2012 10:51:08 PM

Post# of 257253
Portola will start phase-3 trial of Betrixaban in VTE prevention of acute hospitalized patients, according to JPM presentation:

http://finance.yahoo.com/news/Portola-J-P-Morgan-Healthcare-iw-1377695786.html?x=0

Good luck with that! This is an indication where Xarelto and Eliquis both failed in phase-3 trials (#msg-61803303, #msg-68938689).

Betrixaban used to partnered with MRK, but MRK dumped the program in early 2011 (#msg-61300408).

p.s. I was bearish on Betrixaban five years ago (#msg-21106352) and not much has changed since then, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now